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Hospitalized Heart Failure*Stephen J. Greene, MD, Mihai Gheorghiade, MDSEE PAGE 1591D espite available therapies and quality im-provement initiatives, within 90 days ofdischarge, hospitalized patients with heart
failure (HF) experience post-discharge mortality
and rehospitalization rates as high as 15% and 30%,
respectively (1,2). With 1 possible exception (3), a
decade of large phase III trials with novel and exist-
ing agents failed to reduce the high post-discharge
event rate (4–7). The reasons likely include sub-
optimal understanding of the drug mechanism, the
hospitalized HF population’s heterogeneity, and
a failure to match the study drug to the subset
of patients most likely to beneﬁt. Ideally, a precise
hospitalized HF subpopulation at particularly high
risk of a speciﬁc outcome would be aligned with a
therapy selectively targeting that outcome’s sus-
pected mechanism of occurrence. A nuanced under-
standing of the modes and temporal distribution of
death and competing risks for post-discharge adverse
events affecting hospitalized patients with HF is
needed.
In this issue of the Journal, Felker et al. (8) exam-
ined the RELAX-AHF (Relaxin in Acute Heart Failure)*Editorials published in the Journal of the American College of Cardiology
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with HF within 16 h of presentation to a 48-h infusion
of either serelaxin or placebo. Although not primary
study endpoints, cardiovascular and all-cause mor-
tality were reduced with serelaxin at 180-day follow-
up (3). During this period, there were 107 total
deaths; 82% were cardiovascular related. HF,sudden cardiac death (SCD), and other cardiovascular
death accounted for 35%, 23%, and 24%, respec-
tively, of total deaths. Serelaxin treatment was
associated with a statistically signiﬁcant reduction in
other cardiovascular deaths and a trend toward a
reduction of SCD frequency and did not apparently
inﬂuence HF or noncardiovascular death. Nearly
half (49) of all deaths occurred within 60 days of
randomization; all but 3 of these were cardiovascular
related.
Although the researchers rigorously assessed
treatment effect by mode of death (8), the small
number of events unfortunately prevents a deﬁnitive
determination of serelaxin’s potential mechanism of
beneﬁt. Although the results of Felker et al. are
encouraging, it is difﬁcult to reconcile the main
mortality ﬁndings of the RELAX-AHF trial with those
of the current HF treatment paradigm because no
short-term therapy for hospitalized or chronic HF
has previously demonstrated long-term beneﬁt. We
eagerly await the results of an ongoing large phase III
outcome trial (NCT01870778) that will further deﬁne
serelaxin’s effect on mortality.
Understanding the causes of death and rehospi-
talization in hospitalized patients with HF is critical
for developing treatment strategies to prevent these
events. As noted by Felker et al. (8), the EVEREST
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FIGURE 1 Timing of Primary Modes of Death From the
EVEREST Trial
HF ¼ heart failure; SCD ¼ sudden cardiac death. Reprinted with
permission from O’Connor et al. (9).
Greene and Gheorghiade J A C C V O L . 6 4 , N O . 1 5 , 2 0 1 4
Drug Development for Hospitalized HF O C T O B E R 1 4 , 2 0 1 4 : 1 5 9 9 – 6 0 1
1600(Efﬁcacy of Vasopressin Antagonism in Heart Failure
Outcome Study with Tolvaptan) trial (9) offers the
only prior comprehensive characterization of mode of
death in hospitalized patients with HF. The RELAX-
AHF data contrast with those from the EVEREST
trial, in which HF death, SCD, and other cardiac death
(including myocardial infarction, stroke, and un-
known) rates were approximately 41%, 26%, and 20%
of total deaths, respectively. The absolute mortality
rate was also signiﬁcantly higher in the EVEREST
trial, at 26.1% over a median 9.9-month follow-up
time. Moreover, although the EVEREST trial had a
longer follow-up period, 73% of deaths occurred after
>60 days of follow-up (Figure 1). As indicated by
Felker et al. (8), these outcome differences between
trials coincide with substantial differences in their
respective patient populations in terms of ejection
fraction, blood pressure, background therapy, and
comorbidities, among others. Importantly, compari-
son of the RELAX-AHF and EVEREST outcome data
allows us to appreciate the linkage between the hos-
pitalized HF patient proﬁle and patterns of post-
discharge outcomes in the clinical trial setting.
Recently, the hospitalized HF population’s in-
herent heterogeneity, in terms of comorbidities, pre-
sentation, and myocardial substrate, has received
increasing attention (10). Models have used these
characteristics for risk stratiﬁcation and prediction of
post-discharge events (11). However, the hospitalized
patient with HF proﬁle may not only correlate with
overall risk of adverse events but also with speciﬁctypes of events. Likewise, the competing risk
concept deserves careful consideration; hospitalized
HF subsets may differ in their most common mecha-
nism of death and thus in their beneﬁt from different
investigational therapies. Similarly, a given therapy
may preferentially reduce risk of death via one
mechanism (e.g., SCD) at the expense of another
(e.g., HF death).
For example, although implantable cardioverter-
deﬁbrillators (ICDs) are a guideline-based therapy
for patients with chronic HF with New York Heart
Association class II and III symptoms (12), retrospec-
tive analysis of hospitalized patients with HF by ICD
status with similar discharge functional class did not
yield an independent association with all-cause or
cardiovascular mortality (13). However, the results
suggested that ICD therapy affects mode of death;
patients in the ICD group had lower SCD rates and
higher HF death rates than the group without devices.
Off-setting of the modes of death is also conceivable
in drug trials. In the prospective DIG trial, digoxin’s
beneﬁt on HF death in patients with chronic HF
appeared neutralized by increased arrhythmic and
other cardiovascular deaths, yielding no net mortality
effect (14).
The challenge of competing post-discharge risks in
hospitalized HF is further complicated by rehospi-
talization rates (15). Because patients who die
following discharge cannot be readmitted, correlation
between mortality and rehospitalization may be poor
(15,16). Similarly, therapies that decrease mortality
rates could negatively affect hospitalization. The
aforementioned analysis of ICD status in hospitalized
patients with HF found that the presence of a device
independently predicted HF readmission, despite the
potential beneﬁt on SCD risk (13). Plausibly, ICD
therapy could save a patient from dying but result in
subsequent readmission for HF or high-frequency
right ventricular pacing or inappropriate shocks that
could worsen HF. Although it should not be manda-
tory for a novel hospitalized HF therapy to reduce
both cardiovascular mortality and HF readmission,
improving one at the other’s expense would be con-
cerning. Likewise, if an investigational therapy’s
mechanism of action favors decreased mortality over
decreased rehospitalization (or vice versa), the trial
population should be tailored accordingly, with
consideration of patient characteristics that may
predict risk of death versus risk of readmission (15).
Accounting for varying hospitalized HF patient
proﬁles and corresponding speciﬁc post-discharge
adverse event risks is a difﬁcult but important chal-
lenge for future trials. To date, large phase III pro-
grams have repeatedly failed to replicate encouraging
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1601phase II study results (17). To reverse this trend
necessitates consideration of at least 2 important
points. First, ﬁne tuning of optimal study inclusion/
exclusion criteria requires further deﬁnition of hos-
pitalized HF patient subgroups and associated out-
comes. This may be facilitated via a pre-trial registry
and continued examination of existing registry and
trial data (18). Moreover, natriuretic peptide levels
and other novel biomarkers may help to delineate
relative HF death versus SCD risks (19). Secondly,
rigorous testing in small homogenous cohorts in
early-phase trials of the study therapy will maximally
elucidate the mechanism of action and beneﬁt, thus
generating substantial biological plausibility for
pairing the therapy with the subsequent phase III trial
population (20).
In conclusion, besides providing novel insights
regarding mode and temporal distribution of death
in a unique hospitalized HF cohort, the analyses ofFelker et al. remind us to reﬂect on the speciﬁc type
and mechanism of adverse outcome being targeted
with future hospitalized HF trials. Patients hospital-
ized with HF die for multiple reasons. We must de-
ﬁne select patient subgroups and the corresponding
most likely mechanism of death to facilitate optimal
matching of patients with the study therapy. Aligning
a therapy with a well-deﬁned mechanism for beneﬁt
with the hospitalized HF subpopulation at height-
ened risk of a speciﬁc adverse event will maximize
chances of identifying a treatment that improves
post-discharge outcomes.
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